Home/Pipeline/EPIM-001

EPIM-001

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Elpis Biopharmaceuticals

About Elpis Biopharmaceuticals

Elpis Biopharmaceuticals is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, USA, with an additional presence in Singapore. The company is focused on developing novel bispecific armored CAR-T cell therapies and immuno-modulators to treat solid tumors, a significant unmet medical need. Its core strategy leverages proprietary platforms for multi-antigen targeting and armored cell engineering to improve efficacy and durability. Elpis's lead programs target glioblastoma and a broad range of solid tumors, positioning it in the competitive but high-potential field of next-generation cell therapy.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed